44 results on '"Lichtenstein, Gary R"'
Search Results
2. Correction: ACG Clinical Guideline: Management of Crohn’s Disease in Adults
3. Evaluation of bone mineral density in inflammatory bowel disease: current safety focus
4. The effects of infliximab maintenance therapy on health-related quality of life
5. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
6. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
7. Corticosteroids in Crohn’s disease
8. An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis
9. Integrating anti–tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives
10. Use of a push enteroscope improves ability to perform total colonoscopy in previously unsuccessful attempts at colonoscopy in adult patients
11. Management of Crohn's Disease in Adults
12. Monitoring 6-Mercaptopurine/Azathioprine Metabolite Levels
13. Medical Management of Crohn's Disease in 2006: What's on the Horizon?
14. Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease
15. PRO: Maintenance Therapy Is Superior to Episodic Therapy
16. What Next After Infliximab?
17. Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis
18. Heterotopic pancreas presenting as dysphagia
19. Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient
20. The safety of budesonide: a global analysis
21. Conventional Crohn’s disease activity index definition of remission dose not predict patient’s perception of disease activity with high specificity
22. Does increased body mass index delay diagnosis of Crohn’s disease?
23. Does elevated body mass index affect the clinical course of Crohn’s disease?
24. Smoking and surgical risk in Crohn’s disease patients treated with infliximab; does smoking increase the incidence of subsequent surgery?
25. Maintenance treatment with infliximab reduces hospitalizations and surgeries/procedures in patients with fistulizing Crohn’s Disease
26. High rates of disability and unemployment in patients with fistulizing Crohn’s Disease
27. Sustained remission lowers the likelihood of hospitalization and surgery in patients with Crohn’s Disease
28. Strictures and response to infliximab in Crohn’s Disease
29. Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn’s Disease patients: accent I study results
30. Magnification and chromoendoscopy in the detection of colorectal neoplasia in patients with ulcerative colitis
31. Coherin™ peptides effectively maintain remission in patients with Crohn’s disease for 2 years
32. Coherin™ peptides induce clinical response and remission in patients with ulcerative colitis
33. Coherin™ peptides induce clinical response and remission in patients with active Crohn’s disease
34. Balsalazide as salvage therapy for mesalamine failure/intolerance in patients with ulcerative colitis
35. Response to infliximab in Crohn’s disease: do strictures make a difference?
36. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
37. Infliximab (Remicade) treatment allows Crohns disease to reduce or discontinue concomitant corticosteroid use
38. Extraintestinal manifestations of Crohns disease: response to infliximab (Remicade®) in the ACCENT I trial through 30 weeks
39. Impact of Crohn’s disease on work status
40. Infliximab tolerability in Crohn’s disease patients
41. Crohn’s disease severity and treatments: impact on IBDQ scores
42. Diagnosis of Crohn’s disease: a wolf in sheep’s clothing?
43. Ileal thickening on abdominal CT scanning: radiographic features predictive of Crohn’s disease
44. Pouchitis associated with primary cytomegalovirus infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.